Breaking News Instant updates and real-time market news.

AOI

Alliance One

$14.75

-0.275 (-1.83%)

, DOMO

Domo

$18.83

-0.37 (-1.93%)

08:30
07/19/18
07/19
08:30
07/19/18
08:30

Six new option listings and one option delisting on July 19th

New option listings for July 19th include Alliance One (AOI), Domo Inc (Class B Stock) (DOMO), Gemphire Therapeutics (GEMP), Maxar Technologies Ltd (MAXR), UroGen Pharma (URGN), and Veoneer Inc (VNE). Option delistings effective July 19th include Validus Holdings Ltd (VR).

AOI

Alliance One

$14.75

-0.275 (-1.83%)

DOMO

Domo

$18.83

-0.37 (-1.93%)

GEMP

Gemphire Therapeutics

$7.90

0.12 (1.54%)

MAXR

Maxar Technologies

$52.13

-0.51 (-0.97%)

URGN

UroGen Pharma

$47.85

-0.15 (-0.31%)

VNE

Veoneer

$51.53

1.75 (3.52%)

VR

Validus

$67.99

(0.00%)

  • 31

    Jul

  • 12

    Sep

AOI Alliance One
$14.75

-0.275 (-1.83%)

DOMO Domo
$18.83

-0.37 (-1.93%)

07/13/18
SUSQ
07/13/18
INITIATION
Target $24
SUSQ
Positive
Domo initiated with a Positive on solid product offering at Susquehanna
Susquehanna analyst Anne Meisner initiated Domo with a Positive and $24 price target based on a solid product offering and confidence in the seasoned management team. Mesiner said shares trade at a deep discount to other high-growth software companies, which is deserved given competitive dynamics and cash burn, but said the company is investing to capture a significant market opportunity, and devoted substantial amounts of capital to R&D and sales & marketing.
07/13/18
SUSQ
07/13/18
INITIATION
Target $24
SUSQ
Positive
Domo initiated with a Positive at Susquehanna
Susquehanna analyst Anne Meisner initiated Domo with a Buy and $24 price target.
07/13/18
07/13/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Galmed (GLMD) initiated with a Buy at Stifel. 2. Oshkosh (OSK) initiated with a Buy at Longbow. 3. Domo (DOMO) was initiated with a Positive at Susquehanna and an Outperform at Oppenheimer. 4. ADMA Biologics (ADMA) initiated with an Outperform at Oppenheimer. 5. Urban Outfitters (URBN) initiated with a Neutral at Wedbush and an Outperform at Wedbush. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
GEMP Gemphire Therapeutics
$7.90

0.12 (1.54%)

12/22/17
ROTH
12/22/17
NO CHANGE
Target $30
ROTH
Buy
Gemphire transition to NASH a value creator, says Roth Capital
Roth Capital analyst Yasmeen Rahimi views Gemphire Therapeutics' transition into non-alcoholic steatohepatitis as an "important shareholder value creator." After the company announced the launch of proof-of-concept Phase 2a trial of gemacabene in eight patients with familial partial lipodystrophy, a rare genetic metabolic condition characterized by abnormal distribution of subcutaneous fat which then leads to NASH, the analyst keeps a Buy rating on Gemphire with a $30 price target.
01/26/18
HCWC
01/26/18
NO CHANGE
Target $28
HCWC
Buy
Gemphire Therapeutics price target raised to $28 from $22 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce raised his price target for Gemphire Therapeutics to $28 saying he sees a "catalyst-rich" 2018 for the company. The analyst says his confidence grows in the emerging multiple mechanisms of the compound as the gemcabene pipeline expands. He keeps a Buy rating on Gemphire Therapeutics.
10/19/17
ROTH
10/19/17
INITIATION
Target $30
ROTH
Buy
Gemphire Therapeutics initiated with a Buy at Roth Capital
Roth Capital analyst Yasmeen Rahimi started Gemphire Therapeutics with a Buy rating and $30 price target driven by her confidence in the clinical success of the company's one and only candidate for the treatment of dyslipidemia and fatty liver disease.
05/16/18
RAJA
05/16/18
INITIATION
Target $22
RAJA
Outperform
Gemphire Therapeutics initiated with an Outperform at Raymond James
Raymond James analyst Laura Chico initiated Gemphire Therapeutics with an Outperform and $22 price target saying its gemcabene offs a potentially differentiated profile in the dyslipidemia space, which should narrow the gap versus peers with successful data.
MAXR Maxar Technologies
$52.13

-0.51 (-0.97%)

05/10/18
SCOT
05/10/18
DOWNGRADE
SCOT
Sector Perform
Maxar Technologies downgraded to Sector Perform from Outperform at Scotiabank
03/19/18
03/19/18
UPGRADE
Target $80

Outperform
Maxar Technologies upgraded to Outperform from Market Perform at Raymond James
As previously reported, Raymond James upgraded Maxar Technologies to Outperform from Market Perform and increased its price target to $80 from $59. Analsyt Steven Li believes the recent pullback is a "little overdone" as concerns on the Com Sat space appear to be reflected in valuation. Li sees revenue troughing, capex peaking, and cash flow growing substantially over the next two years, and sees material upside from large contract opportunities.
03/19/18
RAJA
03/19/18
UPGRADE
RAJA
Outperform
Maxar Technologies upgraded to Outperform from Market Perform at Raymond James
03/15/18
FBCO
03/15/18
DOWNGRADE
Target $52
FBCO
Neutral
Maxar Technologies downgraded to Neutral from Outperform at Credit Suisse
Credit Suisse analyst Robert Spingarn downgraded Maxar Technologies to Neutral with a $52 price target. While the DigitalGlobe acquisition and U.S. Access Plan provide "significant opportunities" longer term, the current target of $1B in EBITDA by 2022 is optimistic, Spingarn tells investors in a research note. He prefers to step to the sidelines pending better clarity on execution and end-market growth.
URGN UroGen Pharma
$47.85

-0.15 (-0.31%)

11/15/17
RAJA
11/15/17
DOWNGRADE
RAJA
Market Perform
UroGen Pharma downgraded to Market Perform from Outperform at Raymond James
As previously reported, Raymond James downgraded UroGen Pharma to Market Perform from Outperform. Analyst Reni Benjamin said shares have surpassed his bull case target of $33 and valuation reflects the commercial prospects and risks of the pipeline products including MitoGel and VesiGel.
03/16/18
LTCO
03/16/18
NO CHANGE
Target $65
LTCO
Buy
UroGen Pharma price target raised to $65 from $50 at Ladenburg
Ladenburg Thalmann analyst Matthew Kaplan raised his price target for UroGen Pharma to $65 and reiterates a Buy rating on the shares following the company's Q4 results. Interim Phase 3 MitoGel data for the treatment of low-grade upper tract urothelial carcinoma are expected in Q2. Kaplan tells investors in a research note. The analyst is encouraged by the Phase 2 results and believe there is strong likelihood for a positive readout for the study.
04/06/18
OPCO
04/06/18
NO CHANGE
Target $75
OPCO
Outperform
UroGen Pharma price target raised to $75 from $62 at Oppenheimer
Oppenheimer analyst Derek Archila raised his price target on UroGen Pharma to $75 from $62. Archila told investors in a research note that he is increasing his probability of success for MitoGel in upper tract urothelial carcinoma, or UTUC, based on "impressive" interim results from its OLYMPUS Phase 3 study, in which the complete response rate was better than seen in the compassionate use study. Archila reiterated an Outperform rating on UroGen shares.
04/04/18
RAJA
04/04/18
UPGRADE
RAJA
Outperform
UroGen Pharma upgraded to Outperform from Market Perform at Raymond James
VNE Veoneer
$51.53

1.75 (3.52%)

07/17/18
MZHO
07/17/18
INITIATION
Target $60
MZHO
Buy
Veoneer initiated with a Buy at Mizuho
Mizuho initiated Veoneer with a Buy and $60 price target.
07/18/18
07/18/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Veoneer (VNE) initiated with a Buy at Mizuho and a Neutral at Citi. 2. Huntsman (HUN) initiated with an Outperform at RBC Capital. 3. Autoliv (ALV) reinstated with a Sell at Societe Generale. 4. Chemours (CC) initiated with an Outperform at RBC Capital. 5. VF Corp. (VFC) initiated with an Outperform at RBC Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/18/18
MZHO
07/18/18
INITIATION
Target $60
MZHO
Buy
Mizuho starts 'key enabler' Veoneer with Buy rating, $60 target
Mizuho analyst Vijay Rakesh last night initiated coverage of Veoneer with a Buy rating and $60 price target. The company is a "key enabler in the secular shift" in automotive from advanced driver assistance to highly automated and autonomous driving, Rakesh told investors in a research note. Veoneer is expected to grow to $4B in revenue by 2022 with active safety growing annually at 23%, the analyst points out.
07/18/18
SBSH
07/18/18
INITIATION
Target $51
SBSH
Neutral
Veoneer initiated with a Neutral at Citi
Citi analyst Itay Michaeli started Veoneer with a Neutral rating and $51 price target. The analyst also opened up a 90 day "upside catalyst watch" for the shares. The analyst believes Veoneer "still hasn't proven itself as a technology leader in higher-end level-2+ features." The analyst, however, is "fundamentally constructive" on the company's near-term news flow potential with regards to new advanced driver assistance system awards.
VR Validus
$67.99

(0.00%)

02/13/18
BUCK
02/13/18
DOWNGRADE
BUCK
Neutral
Validus downgraded to Neutral from Buy at Buckingham
Validus (VR) is being acquired by AIG (AIG) for $68 per share in cash.
02/13/18
02/13/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Weatherford (WFT) downgraded to Equal Weight from Overweight at Barclays with analyst J. David Anderson saying there is only so much new CEO Mark McCollum can do given the company's $7.1B of net debt and the "low hanging cost opportunities already picked" in the third year of a "turnaround." 2. BP (BP) downgraded to Equal Weight from Overweight at Morgan Stanley. 3. Eversource (ES) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Stephen Byrd citing a New Hampshire state committee denial of the company's Northern Pass Transmission project. 4. AvalonBay (AVB) downgraded to Neutral on relative market growth at BofA/Merrill with analyst Juan Sanabria saying AvalonBay's core has been disappointing versus peers and sees risks around developments in the current supply environment, specifically in New York City. 5. Validus (VR) downgraded to Neutral from Buy at Buckingham. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/22/18
KBWI
01/22/18
DOWNGRADE
KBWI
Market Perform
Validus downgraded to Market Perform from Outperform at Keefe Bruyette
Keefe Bruyette analyst Meyer Shields downgraded Validus (VR) following the takeover by AIG (AIG).
01/30/18
JMPS
01/30/18
DOWNGRADE
JMPS
Market Perform
Validus downgraded to Market Perform from Outperform at JMP Securities
JMP Securities analyst Matthew Carletti downgraded Validus (VR) to Market Perform following the acquisition by AIG (AIG) for $68 per share in cash saying it is a fair price for the company.

TODAY'S FREE FLY STORIES

COST

Costco

$248.62

-0.93 (-0.37%)

17:11
05/23/19
05/23
17:11
05/23/19
17:11
Recommendations
Costco analyst commentary  »

Baird recommends…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

MYND

MYnd Analytics

$1.16

0.14 (13.73%)

17:06
05/23/19
05/23
17:06
05/23/19
17:06
Hot Stocks
MYnd Analytics director John Pappajohn purchases 200K shares of company stock »

MYnd Analytics director…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBOE

Cboe Global Markets

$106.40

-1.45 (-1.34%)

17:05
05/23/19
05/23
17:05
05/23/19
17:05
Hot Stocks
Cboe Global Markets EVP Harkins sells 4.3K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGNX

MacroGenics

$18.64

0.18 (0.98%)

16:56
05/23/19
05/23
16:56
05/23/19
16:56
Hot Stocks
Integrated Core Strategies reports 5.7% passive stake in MacroGenics »

Integrated Core…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

IMRN

Immuron

$4.90

(0.00%)

16:49
05/23/19
05/23
16:49
05/23/19
16:49
Syndicate
Immuron announces offering to sell ADSs »

Immuron Limited announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROLL

RBC Bearings

$140.52

1.84 (1.33%)

16:47
05/23/19
05/23
16:47
05/23/19
16:47
Hot Stocks
RBC Bearings announces $100M share repurchase program »

RBC Bearings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 05

    Jun

DVAX

Dynavax

$6.36

(0.00%)

16:47
05/23/19
05/23
16:47
05/23/19
16:47
Hot Stocks
Dynavax to restructure to focus on vaccine business »

Dynavax Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 31

    May

  • 05

    Jun

CNC

Centene

$55.45

-1.33 (-2.34%)

, WCG

WellCare

$274.46

-3.54 (-1.27%)

16:45
05/23/19
05/23
16:45
05/23/19
16:45
Hot Stocks
Centene, WellCare announce special meeting date, transaction to close by 1H20 »

Centene (CNC) and…

CNC

Centene

$55.45

-1.33 (-2.34%)

WCG

WellCare

$274.46

-3.54 (-1.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 14

    Jun

  • 23

    Jul

DVAX

Dynavax

$6.36

(0.00%)

16:42
05/23/19
05/23
16:42
05/23/19
16:42
Hot Stocks
Breaking Hot Stocks news story on Dynavax »

Dynavax trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 31

    May

  • 05

    Jun

DNKEY

Danske Bank

$0.00

(0.00%)

16:39
05/23/19
05/23
16:39
05/23/19
16:39
Downgrade
Danske Bank rating change at Goldman Sachs »

Danske Bank downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WD

Walker & Dunlop

$51.59

-0.92 (-1.75%)

16:39
05/23/19
05/23
16:39
05/23/19
16:39
Hot Stocks
Walker & Dunlop President Howard Smith sells $4M in company shares »

Walker & Dunlop…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TD

Toronto-Dominion

$56.01

1.05 (1.91%)

16:36
05/23/19
05/23
16:36
05/23/19
16:36
Downgrade
Toronto-Dominion rating change at National Bank »

Toronto-Dominion…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

16:36
05/23/19
05/23
16:36
05/23/19
16:36
General news
Money Supply M2 Weekly Change data reported »

Week of 5/13 Money Supply…

GWGH

GWG Holdings

$15.25

0.05 (0.33%)

16:36
05/23/19
05/23
16:36
05/23/19
16:36
Hot Stocks
GWG Holdings receives noncompliance notification from Nasdaq »

GWG Holdings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSA

National Storage

$29.80

-0.195 (-0.65%)

16:35
05/23/19
05/23
16:35
05/23/19
16:35
Hot Stocks
National Storage 'elevates' its CEO Arlen Nordhagen to Executive Chairman »

National Storage…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 04

    Jun

16:34
05/23/19
05/23
16:34
05/23/19
16:34
General news
Fed Balance Sheet Level data reported »

Week of 5/22 Fed Balance…

MOS

Mosaic

$21.62

-0.72 (-3.22%)

16:32
05/23/19
05/23
16:32
05/23/19
16:32
Hot Stocks
Mosaic doubles quarterly dividend to 5c per share »

The dividend will be paid…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 29

    May

  • 13

    Nov

ATIS

Attis Industries

$2.15

0.31 (16.85%)

16:32
05/23/19
05/23
16:32
05/23/19
16:32
Hot Stocks
Attis Industries notified by Nasdaq of delinquent Q1 10-Q filing »

Attis Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FLMN

Falcon Minerals

$7.36

-0.26 (-3.41%)

16:32
05/23/19
05/23
16:32
05/23/19
16:32
Initiation
Falcon Minerals initiated at Baird »

Falcon Minerals initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jun

TRPX

Therapix Biosciences

$3.24

-0.03 (-0.92%)

16:31
05/23/19
05/23
16:31
05/23/19
16:31
Hot Stocks
Therapix Biosciences receives Nasdaq noncompliance notification »

Therapix Biosciences Ltd.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQH

AXA Equitable

$20.96

-0.42 (-1.96%)

16:30
05/23/19
05/23
16:30
05/23/19
16:30
Hot Stocks
AXA Equitable raises quarterly dividend to 15c from 13c per share »

The dividend will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 11

    Jun

DIS

Disney

$132.78

-1.06 (-0.79%)

16:28
05/23/19
05/23
16:28
05/23/19
16:28
Periodicals
ESPN's Pitaro says 'all hands on deck' to draw younger viewers, Bloomberg says »

ESPN president Jimmy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 25

    Jun

CALX

Calix

$6.38

-0.25 (-3.77%)

16:27
05/23/19
05/23
16:27
05/23/19
16:27
Hot Stocks
Calix director Kevin Denuccio purchases over $221K in company shares »

Calix director Kevin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

BBY

Best Buy

$65.79

-3.47 (-5.01%)

, AAPL

Apple

$179.67

-2.94 (-1.61%)

16:25
05/23/19
05/23
16:25
05/23/19
16:25
On The Fly
Fly Intel: Wall Street's top stories for Thursday »

Stocks suffered losses…

BBY

Best Buy

$65.79

-3.47 (-5.01%)

AAPL

Apple

$179.67

-2.94 (-1.61%)

FB

Facebook

$180.89

-4.36 (-2.35%)

AVP

Avon Products

$3.61

-0.46 (-11.30%)

MAXR

Maxar Technologies

$8.84

1.69 (23.64%)

BX

Blackstone

$41.14

-0.56 (-1.34%)

PLD

Prologis

$76.44

-0.13 (-0.17%)

LB

L Brands

$24.27

-0.02 (-0.08%)

GWR

Genesee & Wyoming

$94.01

7.945 (9.23%)

BLMN

Bloomin' Brands

$18.22

-1.98 (-9.80%)

CMG

Chipotle

$666.31

-39.74 (-5.63%)

NTAP

NetApp

$61.65

-0.93 (-1.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 23

    May

  • 29

    May

  • 30

    May

  • 30

    May

  • 30

    May

  • 03

    Jun

  • 03

    Jun

  • 03

    Jun

  • 04

    Jun

  • 06

    Jun

  • 11

    Jun

  • 11

    Jun

  • 25

    Jun

  • 27

    Jun

  • 09

    Jul

  • 09

    Jul

  • 22

    Aug

  • 13

    Nov

BX

Blackstone

$41.14

-0.56 (-1.34%)

, BAM

Brookfield

$46.55

-0.25 (-0.53%)

16:23
05/23/19
05/23
16:23
05/23/19
16:23
Periodicals
Genesee & Wyoming pursued by Blackstone, Brookfield, others, Bloomberg says »

Blackstone (BX),…

BX

Blackstone

$41.14

-0.56 (-1.34%)

BAM

Brookfield

$46.55

-0.25 (-0.53%)

GWR

Genesee & Wyoming

$94.01

7.945 (9.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Jun

  • 19

    Jun

  • 08

    Aug

  • 13

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.